STREAMLINE HEALTH SOLUTIONS (STRM)
US86323X1063 - Common Stock
Taking everything into account, STRM scores 1 out of 10 in our fundamental rating. STRM was compared to 39 industry peers in the Health Care Technology industry. STRM may be in some trouble as it scores bad on both profitability and health. STRM does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year STRM has reported negative net income.
STRM had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: STRM reported negative net income in multiple years.
In the past 5 years STRM always reported negative operating cash flow.
1.2 Ratios
STRM's Return On Assets of -48.23% is on the low side compared to the rest of the industry. STRM is outperformed by 67.57% of its industry peers.
Looking at the Return On Equity, with a value of -118.40%, STRM is doing worse than 64.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.23% | ||
| ROE | -118.4% | ||
| ROIC | N/A |
ROA(3y)-24.63%
ROA(5y)-13.26%
ROE(3y)-50.21%
ROE(5y)-27.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
STRM has a Gross Margin (50.86%) which is comparable to the rest of the industry.
In the last couple of years the Gross Margin of STRM has declined.
STRM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.81%
GM growth 5Y-4.29%
2. Health
2.1 Basic Checks
STRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STRM has been increased compared to 1 year ago.
The number of shares outstanding for STRM has been increased compared to 5 years ago.
STRM has a worse debt/assets ratio than last year.
2.2 Solvency
STRM has an Altman-Z score of -4.37. This is a bad value and indicates that STRM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.37, STRM is doing worse than 70.27% of the companies in the same industry.
STRM has a Debt/Equity ratio of 0.66. This is a neutral value indicating STRM is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.66, STRM is doing worse than 72.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.37 |
ROIC/WACCN/A
WACC10.19%
2.3 Liquidity
A Current Ratio of 0.61 indicates that STRM may have some problems paying its short term obligations.
STRM has a Current ratio of 0.61. This is amonst the worse of the industry: STRM underperforms 86.49% of its industry peers.
A Quick Ratio of 0.61 indicates that STRM may have some problems paying its short term obligations.
With a Quick ratio value of 0.61, STRM is not doing good in the industry: 86.49% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.61 | ||
| Quick Ratio | 0.61 |
3. Growth
3.1 Past
The earnings per share for STRM have decreased strongly by -670.00% in the last year.
Looking at the last year, STRM shows a very negative growth in Revenue. The Revenue has decreased by -15.66% in the last year.
Measured over the past years, STRM shows a small growth in Revenue. The Revenue has been growing by 0.20% on average per year.
EPS 1Y (TTM)-670%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1775%
Revenue 1Y (TTM)-15.66%
Revenue growth 3Y25.8%
Revenue growth 5Y0.2%
Sales Q2Q%-22.43%
3.2 Future
Based on estimates for the next years, STRM will show a small growth in Earnings Per Share. The EPS will grow by 6.63% on average per year.
The Revenue is expected to decrease by -4.24% on average over the next years.
EPS Next Y-2%
EPS Next 2Y6.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-11.86%
Revenue Next 2Y-4.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
STRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STRM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.63%
EPS Next 3YN/A
5. Dividend
5.1 Amount
STRM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
STREAMLINE HEALTH SOLUTIONS
NASDAQ:STRM (10/17/2024, 9:05:38 PM)
After market: 2.2293 +0.07 (+3.21%)2.16
-0.27 (-11.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.23% | ||
| ROE | -118.4% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.86% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.61 | ||
| Quick Ratio | 0.61 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-670%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-2%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.66%
Revenue growth 3Y25.8%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y